Breaking barriers: Upfront expense payments to ease the economic burden for clinical trial patients.

e23160 Background: Participation in clinical trials (CT) often imposes significant challenges on patients, beyond emotional and time commitments. The economic burden associated with being out-of-pocket (OOP) is a major barrier, particularly for individuals from lower socio-economic backgrounds, limiting their participation and retention in CT. Currently, Patients are required to cover their expenses upfront themselves, retain receipts, and submit claims for reimbursement. This process can take weeks, causing financial strain on patients, making CT less accessible to certain patient groups. To address this issue, we have developed an efficient and streamlined upfront payment management process to minimise the economic and administrative burden for both patients and CT sites. Methods: A collaboration between the Drug Development Unit at the Royal Marsden (RM) and the Institute of Cancer Research, Public and Patient Group at the RM, Barts NHS Trust, Vall d' Hebron Institute of Oncology, Clinica Universidad de Navarra, Roche/Genentech and third-party vendor, Greenphire, tackled key challenges such as Logistics of payment processes, Tax implications, Fiscal impact on trial sponsor, Country specific aspects and Regulatory and Ethics approval for the process, piloting in one of the Roche/Genentech sponsored trial AND finding solutions for these challenges. Results: A comprehensive upfront payment process (Table 1) was designed to support patients from pre-consent through to trial completion. Key features are: Tax-exempt paymentsReasonable OOP expenses are exempt from Tax implications. Individualized expense assessmentPayments are calculated per CT visit based on national guidelines and documented for audits. Seamless patient paymentsA portal within Greenphire facilitated real time direct payments via debit card or bank transfer where allowable. Regulatory integrationUK regulatory approval was secured. Approval in Spain is on-going. Conclusions: The upfront payment process effectively minimizes OOP expenses, reduces site burden, and improves the patient experience. Addressing other barriers, eg childcare, carer and pet-care, will further enhance CT accessibility, ultimately fostering a more equitable environment. Expanding this process across more CT will improve inclusivity and diversity and will provide measurable outcomes. · Pre-consent Patients OOP expenses are assessed prior to consent visit. · Informed Consent Patient’s consent is obtained before sharing personal details with Greenphire · Payment Set-up Greenphire is informed of patient’s details · First Visit On first consent visit, patients receive OOP expense covering two visits, one for the current visit and one for the next visit, via the Greenphire portal.· Subsequent visits From the second visit onwards, patients received a sum covering their next visit in advance, ensuring patients are never out-of-pocket.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Oncology
Published
2025-05-28
DOI
https://doi.org/10.1200/jco.2025.43.16_suppl.e23160
Primary Topic
Pharmaceutical Economics and Policy
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Breaking barriers: Upfront expense payments to ease the economic burden for clinical trial patients.

Charlotte Ramon, Ruth Davies, Ana Matres Rojo, Laura Arribillaga et al.
Journal of Clinical Oncology
Pharmaceutical Economics and Policy
article

Breaking barriers: Upfront expense payments to ease the economic burden for clinical trial patients.

Charlotte Ramon, Ruth Davies, Ana Matres Rojo, Laura Arribillaga, Chiara Martinelli, Maria Lapuente, Bindumalini Rao Baikady, Aileen M.E. McLeod, Adam Sharp, Mary Van Zyl, Johann Sebastian De Bono, Markella Boudioni, C. Martin Perez, José Manuel Ordóñez, Lyra Del Rosario, Jennifer Ball, Jennifer Lauman, Gabriel Canel, Maria Luisa Bezares, Eric Mackelprang
article en

Abstract

e23160 Background: Participation in clinical trials (CT) often imposes significant challenges on patients, beyond emotional and time commitments. The economic burden associated with being out-of-pocket (OOP) is a major barrier, particularly for individuals from lower socio-economic backgrounds, limiting their participation and retention in CT. Currently, Patients are required to cover their expenses upfront themselves, retain receipts, and submit claims for reimbursement. This process can take weeks, causing financial strain on patients, making CT less accessible to certain patient groups. To address this issue, we have developed an efficient and streamlined upfront payment management process to minimise the economic and administrative burden for both patients and CT sites. Methods: A collaboration between the Drug Development Unit at the Royal Marsden (RM) and the Institute of Cancer Research, Public and Patient Group at the RM, Barts NHS Trust, Vall d' Hebron Institute of Oncology, Clinica Universidad de Navarra, Roche/Genentech and third-party vendor, Greenphire, tackled key challenges such as Logistics of payment processes, Tax implications, Fiscal impact on trial sponsor, Country specific aspects and Regulatory and Ethics approval for the process, piloting in one of the Roche/Genentech sponsored trial AND finding solutions for these challenges. Results: A comprehensive upfront payment process (Table 1) was designed to support patients from pre-consent through to trial completion. Key features are: Tax-exempt paymentsReasonable OOP expenses are exempt from Tax implications. Individualized expense assessmentPayments are calculated per CT visit based on national guidelines and documented for audits. Seamless patient paymentsA portal within Greenphire facilitated real time direct payments via debit card or bank transfer where allowable. Regulatory integrationUK regulatory approval was secured. Approval in Spain is on-going. Conclusions: The upfront payment process effectively minimizes OOP expenses, reduces site burden, and improves the patient experience. Addressing other barriers, eg childcare, carer and pet-care, will further enhance CT accessibility, ultimately fostering a more equitable environment. Expanding this process across more CT will improve inclusivity and diversity and will provide measurable outcomes. · Pre-consent Patients OOP expenses are assessed prior to consent visit. · Informed Consent Patient’s consent is obtained before sharing personal details with Greenphire · Payment Set-up Greenphire is informed of patient’s details · First Visit On first consent visit, patients receive OOP expense covering two visits, one for the current visit and one for the next visit, via the Greenphire portal.· Subsequent visits From the second visit onwards, patients received a sum covering their next visit in advance, ensuring patients are never out-of-pocket.

Journal of Clinical OncologyVol. 43(16_suppl)
St Bartholomew's Hospital (GB), Royal Marsden NHS Foundation Trust (GB), Institute of Cancer Research (GB), Vall d'Hebron Institut de Recerca (ES), Roche (United Kingdom) (GB), Clinica Universidad de Navarra (ES), Roche (Spain) (ES), Vall d'Hebron Institute of Oncology (ES)
Openalex Percentile: Top 83%
Pharmaceutical Economics and Policy
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.